Real-World Data Show Improved Survival With Sacituzumab Govitecan as First-Line ADC in HER2-Low Breast Cancer

Source: Pharmacy Times articles

Sequencing of antibody-drug conjugates (ADCs) in HER2-mutated breast cancer is crucial for optimizing treatment outcomes.
Read More